Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 110.7 5.84% 6.11
ICPT closed up 5.84 percent on Wednesday, December 12, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ICPT trend table...

Date Alert Name Type % Chg
Dec 12 Crossed Above 20 DMA Bullish 0.00%
Dec 12 Crossed Above 50 DMA Bullish 0.00%
Dec 12 Pocket Pivot Bullish Swing Setup 0.00%
Dec 12 NR7 Range Contraction 0.00%
Dec 12 Multiple of Ten Bullish Other 0.00%
Dec 11 20 DMA Resistance Bearish 5.84%
Dec 11 Fell Below 50 DMA Bearish 5.84%
Dec 10 20 DMA Resistance Bearish 4.44%
Dec 10 Crossed Above 50 DMA Bullish 4.44%
Dec 10 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.44%

Older signals for ICPT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Is ICPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 133.74
52 Week Low 51.05
Average Volume 457,671
200-Day Moving Average 90.4289
50-Day Moving Average 104.3068
20-Day Moving Average 106.6215
10-Day Moving Average 108.032
Average True Range 6.2166
ADX 10.64
+DI 19.6018
-DI 16.5329
Chandelier Exit (Long, 3 ATRs ) 96.7002
Chandelier Exit (Short, 3 ATRs ) 111.1998
Upper Bollinger Band 115.3411
Lower Bollinger Band 97.9019
Percent B (%b) 0.73
BandWidth 16.356176
MACD Line 0.685
MACD Signal Line 0.92
MACD Histogram -0.2349
Fundamentals Value
Market Cap 2.78 Billion
Num Shares 25.1 Million
EPS -15.49
Price-to-Earnings (P/E) Ratio -7.15
Price-to-Sales 20.99
Price-to-Book 8.77
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 119.08
Resistance 3 (R3) 118.61 115.35 117.68
Resistance 2 (R2) 115.35 113.22 115.58 117.22
Resistance 1 (R1) 113.03 111.90 114.19 113.49 116.75
Pivot Point 109.77 109.77 110.35 110.00 109.77
Support 1 (S1) 107.44 107.63 108.60 107.91 104.65
Support 2 (S2) 104.18 106.31 104.41 104.18
Support 3 (S3) 101.86 104.18 103.72
Support 4 (S4) 102.32